Cited by 150Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D

Open access

Karreth, Florian A., Frese, Kristopher K., DeNicola, Gina M., Baccarini, Manuela, Tuveson, David A.·2011·Cancer Discovery

DOI 10.1158/2159-8290.cd-10-0044PMC PMC3203527

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Abstract The Ras/Raf/MEK/ERK (extracellular signal–regulated kinase) pathway is primarily responsible for mitogenesis in metazoans, and mutational activation of this pathway is common in cancer. A variety of selective chemical inhibitors directed against the mitogen-activated protein kinase pathway are now available for clinical investigation and thus the determination of the importance of each of the kinases in oncogenesis is paramount. We investigated the role of two Raf kinases, B-Raf and C-Raf, in Ras oncogenesis, and found that although B-Raf and C-Raf have overlapping functions in primary mesenchymal cells, C-Raf but not B-Raf is required for the proliferative effects of K-RasG12D in primary epithelial cells. Furthermore, in a lung cancer mouse model, C-Raf is essential for tumor initiation by oncogenic K-RasG12D, whereas B-Raf is dispensable for this process. Our findings reveal that K-RasG12D elicits its oncogenic effects primarily through C-Raf and suggest that selective C-Raf inhibition could be explored as a therapeutic strategy for K-Ras–dependent cancers. Significance: Ras is one of the most prevalent oncogenes in human cancer; however, it is considered “undruggable.” Therefore, increasing our understanding of the importance of Ras effectors, including the Raf/MEK/ERK pathway, will create novel avenues for therapeutic intervention. Cancer Discovery; 1(2); 128–36. © 2011 AACR. Read the Commentary on this article by Rebocho and Marais, p. 98 This article is highlighted in the In This Issue feature, p. 91

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-10-0044

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
Self-citation
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citation
Regulation of Raf-1 by direct feedback phosphorylation.
Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 603
Species- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 576

Show all 29 references

Sorted by citations

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850
Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 562
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Targeting the MAPK pathway in KRAS-driven tumors
Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512
Oncogenic KRAS signalling in pancreatic cancer
EŞER, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 528
Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma
Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
Self-citation
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R., Rabinovich, B. A., Hann, B. C., Dankort, D. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 328
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt‐Supprian, M., Rad, R., & Saur, D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.5 · Cited by 322
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 303
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina‐Arcas, M., Steckel, M., East, P., Diefenbacher, M. E., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 269
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Ambrogio, C., Goméz-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez‐Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 178
What We Have Learned About Pancreatic Cancer From Mouse Models
Pérez-Mancera, P. A., Guerra, C. E., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 178
Self-citation
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 168
Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review
Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Dillon, M., Lopez, A. R., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 175
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Mouse models for lung cancer
Kwon, M.-C., & Berns, A. J. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.010 · Cited by 150
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Targeting the RAS oncogene
Takashima, A., & Faller, D. V. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.764990 · Cited by 140
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 138
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
A Braf kinase-inactive mutant induces lung adenocarcinoma
Nieto, P., Ambrogio, C., Esteban-Burgos, L., Goméz-López, G., Blasco, M. T., Yao, Z., Marais, R., Rosen, N. X., Chiarle, R., Pisano, D. G., et al. (2017) · Nature · doi:10.1038/nature23297 · Cited by 122
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126
Alike but Different: RAF Paralogs and Their Signaling Outputs
Desideri, E., Cavallo, A. L., & Baccarini, M. (2015) · Cell · doi:10.1016/j.cell.2015.04.045 · Cited by 119
Self-citation
c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling
Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Montor, W. R., Salas, A. R. O. S. E., & de Melo, F. H. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0792-2 · Cited by 118
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 108
Self-citation
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Ozkan‐Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz‐Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 104
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
Noeparast, A., Teugels, E., Giron, P., Verschelden, G., Brakeleer, S. D., Decoster, L., & Grève, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.11635 · Cited by 98
Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Acquaviva, J., Smith, D. L., Sang, J., Friedland, J. C., He, S., Sequeira, M., Zhang, C., Wada, Y., & Proia, D. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0615 · Cited by 100
Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2
Wang, P., Jia, X., Lu, B., Huang, H., Liu, J., Liu, X., Wu, Q., Hu, Y., Li, P., Wei, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01329-3 · Cited by 99
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
Pino, G. L. G., Li, K., Park, E., Schmoker, A. M., Ha, B. H., & Eck, M. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107207118 · Cited by 95
Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 90
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
Henry, J. R., Kaufman, M. D., Peng, S.-B., Ahn, Y. M., Caldwell, T. M., Vogeti, L., Telikepalli, H., Lu, W.-P., Hood, M. M., Rutkoski, T. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00067 · Cited by 89
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
Rebocho, A. P., & Marais, R. (2012) · Oncogene · doi:10.1038/onc.2012.330 · Cited by 83
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Jones, G. G., del Río, I. B., Sarı, S., Sekerim, A., Young, L. C., Hartig, N., Zubiaur, I. A., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 77
Targeting the MAPK Pathway in RAS Mutant CancersPreprint
Hymowitz, S. G., & Malek, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031492 · Cited by 78
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Yen, I., Shanahan, F., Merchant, M. A., Orr, C., Hunsaker, T., Durk, M. R., La, H., Zhang, X., Martin, S. E., Lin, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.002 · Cited by 77
Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
Danysh, B. P., Rieger, E. Y., Sinha, D. K., Evers, C., Cote, G. J., Cabanillas, M. E., & Hofmann, M.-C. C. (2016) · Oncotarget · doi:10.18632/oncotarget.9023 · Cited by 74
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64
The intermediate-activityL597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayPreprint
Andreadi, C., Cheung, L.-K. M., Giblett, S. M., PATEL, B., Jin, H., Mercer, K., Kamata, T., Lee, P., Williams, A. G., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.193458.112 · Cited by 66
Biomarkers and Targeted Therapy in Pancreatic Cancer
Karandish, F., & Mallik, S. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s34414 · Cited by 82
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux
Wiersma, V. R., de Bruyn, M., Wei, Y., van Ginkel, R. J., Hirashima, M., Niki, T., Nishi, N., Zhou, J., Pouwels, S. D., Samplonius, D. F., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1063767 · Cited by 58
RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
Dorard, C., Estrada, C., Barbotin, C., Larcher, M., Garancher, A., Leloup, J., Beermann, F., Baccarini, M., Pouponnot, C., Larue, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15262 · Cited by 60
Self-citation
Deciphering the RAS/ERK pathway in vivo
Dorard, C., Vucak, G., & Baccarini, M. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160135 · Cited by 53
Self-citation
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 55
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Avery, T. Y., Köhler, N., Zeiser, R., Brummer, T., & Ruess, D. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931774 · Cited by 51
In vivo gene manipulation reveals the impact of stress‐responsive MAPK pathways on tumor progression
Kamiyama, M., Naguro, I., & Ichijo, H. (2015) · Cancer Science · doi:10.1111/cas.12676 · Cited by 50
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 49
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 49
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Venkatanarayan, A., Liang, J., Yen, I., Shanahan, F., Haley, B., Phu, L., Verschueren, E., Hinkle, T. B., Kan, D., Segal, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110351 · Cited by 50
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Nishiguchi, G., Rico, A. C., Tanner, H. R., Aversa, R. J., Taft, B. R., Subramanian, S., Setti, L., Burger, M. T., Wan, L., Tamez, V., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01862 · Cited by 47
Lung tumor growth-promoting function of peroxiredoxin 6
Jo, M., Yun, H., Park, K., Park, M. H., Kim, T. M., Pak, J. H., Lee, S. J., Moon, D. C., Park, C., Song, S., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.032 · Cited by 45
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Griner, L. A. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2033 · Cited by 44
Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling
Wang, J., Yang, M., Xiao, S., Sun, B., Li, Y., & Yang, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0720-8 · Cited by 42
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Wang, P., Laster, K. V., Jia, X., Dong, Z., & Liu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01903-x · Cited by 43
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Riaud, M., Maxwell, J., Soria‐Bretones, I., Dankner, M., Li, M., & Rose, A. A. N. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00650-x · Cited by 40
Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 40
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Thillai, K., Lam, H., Sarker, D., & Wells, C. M. (2016) · Oncotarget · doi:10.18632/oncotarget.13309 · Cited by 37
Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic TargetsPreprint
Drosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 36
Revisiting ovarian cancer preclinical models: Implications for a better management of the disease
Ricci, F., Broggini, M., & Damia, G. L. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.005 · Cited by 35
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis
Jerić, I., Maurer, G., Cavallo, A. L., Raguz, J., Desideri, E., Tarkowski, B., Parrini, M., Fischer, I., Zatloukal, K., & Baccarini, M. (2016) · Nature Communications · doi:10.1038/ncomms13781 · Cited by 35
Self-citation
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 34
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma
Dumaz, N. (2011) · Small GTPases · doi:10.4161/sgtp.2.5.17814 · Cited by 34
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
Kotani, H., Adachi, Y., Kitai, H., Tomida, S., Bando, H., Faber, A. C., Yoshino, T., Voon, D. C., Yano, S., & Ebi, H. (2018) · Oncogene · doi:10.1038/s41388-017-0035-9 · Cited by 32
Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer
Borovski, T., Vellinga, T. T., Laoukili, J., Santo, E. E., Fátrai, S., van Schelven, S., Verheem, A., Marvin, D. L., Ubink, I., Rinkes, I. H. M. B., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311547 · Cited by 31
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis
Kern, F., Doma, E., Rupp, C., Niault, T., & Baccarini, M. (2012) · Oncogene · doi:10.1038/onc.2012.254 · Cited by 30
Self-citation
Ras isoform-specific expression, chromatin accessibility, and signaling
Nussinov, R., Zhang, M., Maloney, R., & Jang, H. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00817-6 · Cited by 29
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status
Dorard, C., Madry, C., Buhard, O., Toifl, S., Didusch, S., Ratovomanana, T., Letourneur, Q., Dolznig, H., Garnett, M. J., Duval, A., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02683-w · Cited by 29
Self-citation
c-Raf in KRas Mutant Cancers: A Moving Target
McCormick, F. P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.017 · Cited by 27
Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways
Fu, N., Xi, R., Shi, X., Li, R., Zhang, Z., Li, L., Zhang, G., & Wang, F. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115988 · Cited by 29
Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum
Pfeiffer, V., Götz, R., Xiang, C., Camarero, G., Braun, A., Zhang, Y., Blum, R., Heinsen, H., Nieswandt, B., & Rapp, U. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058259 · Cited by 26
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation
Jang, D. M., Boxer, K., Ha, B. H., Tkacik, E., Levitz, T. S., Rawson, S. D., Metivier, R. J., Schmoker, A. M., Jeon, H., & Eck, M. J. (2025) · Nature Communications · doi:10.1038/s41467-025-63227-2 · Cited by 27
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 25
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 23
Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Garcia, N., Pozo, V. D., Yohe, M. E., Goodwin, C. M., Shackleford, T. J., Wang, L., Baxi, K., Chen, Y., Rogojina, A. T., Zimmerman, S. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0194 · Cited by 23
Selective CRAF Inhibition Elicits Transactivation
Morgan, C. W., Dale, I. L., Thomas, A. P., Hunt, J., & Chin, J. W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c11958 · Cited by 21
Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 18
Loss of RhoA Exacerbates, Rather Than Dampens, Oncogenic K-Ras Induced Lung Adenoma Formation in Mice
Zandvakili, I., Davis, A. K., Hu, G., & Zheng, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127923 · Cited by 17
A new strategy of using low-dose caffeic acid carbon nanodots for high resistance to poorly differentiated human papillary thyroid cancer
Xin, J., Song, M., Liu, X., Zou, H., Wang, J., Xiao, L., Jia, Y., Zhang, G., Jiang, W., Lei, M., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02792-y · Cited by 16
The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade
Qian, Y., Zhou, L., Luk, S. T. Y., Xu, J., Li, W., Gou, H., Chen, H., Kang, W., Yu, J. Q., & Wong, C. C. (2022) · Oncogene · doi:10.1038/s41388-022-02576-4 · Cited by 16
AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway
Yang, H., Wan, Z., Huang, C., Yin, H., & Song, D. (2018) · Lasers in Medical Science · doi:10.1007/s10103-018-2616-4 · Cited by 15
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14
Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer
Sheridan, C., & Downward, J. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1435s70 · Cited by 14

Authors: Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A.
Affiliations: University of Vienna (AT)
ORCID: Karreth, Florian A.
Frese, Kristopher K.
DeNicola, Gina M.
Baccarini, Manuela
Tuveson, David A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2011-07-01
Volume: 1
Issue: 2
Pages: 128-136
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-10-0044
PMC: PMC3203527
OpenAlex: W2133177414
Cited by: 149
References: 29
Citations by year: 2026: 4 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 8 · 2019: 8 · 2018: 12 · 2017: 11 · 2016: 10 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 8
FWCI: 4.28
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Cancer Research UK (A10211)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: Raf-1, BRAF, lung cancer, RAS/MAPK pathway, carcinogenesis, tumor initiation, Raf kinase inhibition, Ras effectors, epithelial cell proliferation
MeSH terms: Animals, Cell Transformation, Neoplastic, Epithelial Cells, Fibroblasts, Lung, Lung Neoplasms, Mutation, Transformation, Genetic, ras Proteins, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Cell Growth Processes, Mice, Mice, 129 Strain, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks